BridgeBio Pharma BBIO Interest coverage
Interest coverage at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Based on trailing twelve months.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's interest coverage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's interest coverage?
- BridgeBio Pharma (BBIO) reported interest coverage of -7.1× in Q1 2026.
- How has BridgeBio Pharma's interest coverage changed year-over-year?
- BridgeBio Pharma's interest coverage increased by 12.9% year-over-year, from -8.1× to -7.1×.
- What is the long-term trend for BridgeBio Pharma's interest coverage?
- Over 5 years (2020 to 2025), BridgeBio Pharma's interest coverage has grown at a -12.6% compound annual growth rate (CAGR), from -12.9× to -6.6×.
- What does interest coverage mean?
- How many times the company's operating profit covers its interest bill.
- How do you interpret interest coverage?
- Higher is safer; below ~2× is a warning that earnings provide little cushion against the debt burden. Debt-free companies have no interest expense and the ratio is left blank.
- How does interest coverage compare across companies?
- Comparable across leveraged non-financials; less relevant for net-cash companies with negligible interest.